Integra LifeSciences receives approval to purchase DePuy Synthes' neuro division: 5 insights

Mackenzie Garrity -   Print  |

The Federal Trade Commission approved Integra LifeSciences request to purchase DePuy Synthes' Codman Neuro division, according to Reuters.

Here are five insights:


1. In February when the purchase was proposed, the deal was valued at $1.05 billion.


2. To receive approval, Integra LifeSciences sold five medical products lines in a $47.5 million deal to Natus Medical.


3. Product lines Integra sold included systems to monitor pressure inside the skull, three sets of products used to either drain or shunt away excess fluid in the brain and spinal cord, as well as dural grafts used to replace the membrane around the brain or spinal cord to keep fluid in place.


4. Codman Neuro markets devices for neuro-critical care and electrosurgery, and generated sales of approximately $370 million in 2016.


5. After the announcement Wednesday, Integra LifeSciences shares added 0.3 percent to $49.26.


More articles on devices and implants:
16 new spine, orthopedic device launches & releases — Aug. 27, 2017
OrthAlign raises $10M in financing for research & development expansion: 5 insights
Onkos Surgical launches Precision Oncology Platform: 5 key points

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers